source
- Assertio rejects Garda bid, accepts Zydus offer valuing company at $23.50 per shareAssertio Holdings announced it has terminated its pending acquisition by Garda Therapeutics after the board approved a higher offer from another suitor. The new proposal from Zydus Worldwide value…
- Podcast Highlights Community Oncology’s Growing Role in U.S. Cancer CareA new sponsored podcast episode explores how community oncology clinics are becoming a vital part of the U.S. cancer‑care landscape. The program, released in May 2026, discusses why these local cen…